GlassScriptPhysician profile
Candice Johnston
NPI 1447798301
$2,344.37
in general payments reported to CMS, 2019-2025
26 companies · $805 in 2025
The $805 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $165 · 2023: $669 · 2024: $706 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.82 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $397.36 | 2022-2025 | |
| Novo Nordisk INC | $274.22 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $233.03 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Paratek Pharmaceuticals, INC. | $161.93 | 2023-2025 | Nuzyra, Xhance |
| Amgen INC. | $117.72 | 2023-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $82.04 | 2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $72.91 | 2023-2025 | |
| Glaxosmithkline, LLC. | $64.23 | 2024-2025 | Arexvy, Shingrix, Bexsero |
| Idorsia Pharmaceuticals US INC | $57.81 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.82 | 2025 | Caplyta |
| Astellas Pharma US INC | $43.95 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $43.56 | 2023 | Xarelto |
| Axsome Therapeutics, INC. | $42.27 | 2024-2025 | Auvelity |
| Pfizer INC. | $31.64 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.07 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $29.71 | 2024 | Voquezna |
| Medtronic, INC. | $26.57 | 2025 | Intellis Adaptivestim |
| Baxter Healthcare | $26.47 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Neurocrine Biosciences, INC. | $20.82 | 2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $18.88 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.66 | 2023 | |
| Sumitomo Pharma America, INC. | $16.32 | 2023 | Gemtesa |
| Sanofi Pasteur INC. | $14.27 | 2022 | |
| Merck Sharp & Dohme LLC | $13.67 | 2023 | Steglatro, Belsomra, Lagevrio |
| Otsuka America Pharmaceutical, INC. | $13.62 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.